Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
Pharmaceutical Investing SELLAS Life Sciences Group and Cancer Center to Study Galinpepimut-S in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma
Pharmaceutical Investing U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab)
Bristol-Myers Squibb’s Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients
Pharmaceutical Investing Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab)
